Exploration of clinical Biomarkers for guiding treatment selection between chemotherapy and combination therapy with Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Mutant NSCLC patients after EGFR-TKI Therapy: The SPIRAL-STEP study
1. 当前求助状态已完结, 请及时下载应助文件
2. 系统将在 2025-07-25 14:43:25 删除文件
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1016/j.lungcan.2025.108447
文献链接: https://linkinghub.elsevier.com/retrieve/pii/S0169500225000686
其他信息:
出版社: Elsevier BV
作者: Kenji Morimoto; Tadaaki Yamada; Naoki Furuya; Hisashi Tanaka; Akihiro Yoshimura; Tomohiro Oba; Makoto Hibino; Takahito Fukuda; Yasuhiro Goto; Akira Nakao; Shinsuke Ogusu; Yuta Okazaki; Taishi Harada; Takayo Ota; Ken Masubuchi; Koji Mikami; Tae Hata; Shoki Matsumoto; Ryoichi Honda; Koji Date; Yusuke Chihara; Koichi Takayama
